Ironwood Pharmaceuticals Inc (IRWD) concluded trading on Thursday at a closing price of $2.30, with 10.5 million shares of worth about $24.14 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -66.86% during that period and on January 30, 2025 the price saw a loss of about -38.17%. Currently the company’s common shares owned by public are about 160.02M shares, out of which, 155.54M shares are available for trading.
Stock saw a price change of -38.99% in past 5 days and over the past one month there was a price change of -48.31%. Year-to-date (YTD), IRWD shares are showing a performance of -48.08% which decreased to -83.28% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.06 but also hit the highest price of $15.70 during that period. The average intraday trading volume for Ironwood Pharmaceuticals Inc shares is 1.96 million. The stock is currently trading -41.06% below its 20-day simple moving average (SMA20), while that difference is down -40.04% for SMA50 and it goes to -55.85% lower than SMA200.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) currently have 160.02M outstanding shares and institutions hold larger chunk of about 103.14% of that.
The stock has a current market capitalization of $368.07M and its 3Y-monthly beta is at 0.32. It has posted earnings per share of -$0.02 in the same period. It has Quick Ratio of 3.62. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IRWD, volatility over the week remained 16.01% while standing at 9.40% over the month.
Stock’s fiscal year EPS is expected to rise by 100.72% while it is estimated to increase by 262.10% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on September 09, 2024 offering a Market perform rating for the stock and assigned a target price of $5 to it. Coverage by CapitalOne stated Ironwood Pharmaceuticals Inc (IRWD) stock as an Equal weight in their note to investors on August 08, 2024, suggesting a price target of $4 for the stock. On January 17, 2024, Craig Hallum Initiated their recommendations, while on December 14, 2023, Wells Fargo Initiated their ratings for the stock with a price target of $20. Stock get a Buy rating from Jefferies on November 09, 2023.
